Predicting asthma attack risk in real life severe asthma patients on mepolizumab

G. Tavernier (Manchester (Greater Manchester), United Kingdom), L. Whipday (Manchester (Greater Manchester), United Kingdom), T. Qureshi (Manchester (Greater Manchester), United Kingdom), S. Fowler (Manchester (Greater Manchester), United Kingdom)

Source: International Congress 2022 – Severe asthma: from phenotypes to exacerbations

Session: Severe asthma: from phenotypes to exacerbations
Session type: Thematic Poster
Number: 889

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Tavernier (Manchester (Greater Manchester), United Kingdom), L. Whipday (Manchester (Greater Manchester), United Kingdom), T. Qureshi (Manchester (Greater Manchester), United Kingdom), S. Fowler (Manchester (Greater Manchester), United Kingdom). Predicting asthma attack risk in real life severe asthma patients on mepolizumab. 889

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.